Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DAPA-LN trial of dapagliflozin added to maintenance therapy in biopsy-confirmed lupus nephritis
ChiCTR2600131121Phase 4Not yet recruiting
- Sponsor
- The Second Xiangya Hospital
- Start
- Sep 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of dapagliflozin in lupus nephritis (LN) and systemic lupus erythematosus (SLE) (2 arms), sponsored by The Second Xiangya Hospital. Primary endpoints: Renal response rate at 52 weeks, Proportion with at least one predefined clinically significant AESI and 2 more. Planned start Sep 2026; status: not yet recruiting.
02
Drugs
dapagliflozin
03
Conditions
lupus nephritis (LN)systemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on ChiCTR2600131121.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600131121.